Trial · NCT07902778
Hybrid mHealth for Low Back Pain
NCT07902778, Not applicable, Not yet recruiting, The Hong Kong Polytechnic University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Hybrid mHealth for Low Back Pain. Trials, record NCT07902778. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07902778
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Hybrid mHealth for Low Back Pain
- NCT number
- NCT07902778
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 60 participants, estimated
- Lead sponsor
- The Hong Kong Polytechnic University
- Conditions
- Chronic Low-back Pain (cLBP), Non-specific Low Back Pain (NSLBP)
- Interventions
Face-to-face physiotherapy and psychological care (for hybrid arm), WhatsApp-based AI chatbot for self-management (for hybrid and WhatsApp-only arms), Face-to-face physiotherapy and psychological care (No Digital Support) (for control arm)
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pain Intensity (Numeric Rating Scale) | Baseline, 8 weeks, 12 weeks | Change in pain intensity measured on an 11-point Numeric Rating Scale (0 = no pain, 10 = worst possible pain). |
| Primary | Disability score (Roland-Morris Disability Questionnaire) | Baseline, 8 weeks (post-intervention), and 12 weeks (follow-up) | Change in disability as measured by the Roland-Morris Disability Questionnaire (RMDQ); total score ranges from 0 (no disability) to 24 (maximum disability). |
| Primary | Psychological Distress (Depression, Anxiety and Stress Scale-21) | Baseline, 8 weeks, 12 weeks | Change in psychological distress levels as measured by DASS-21. Higher scores indicate greater distress. |
| Secondary | Global Impression of Change Scale | Baseline, 8 weeks, and 12 weeks | Change in participant-reported global impression of symptom change and treatment response using a 7-point scale (from "very much worse" to "very much improved"). |
| Secondary | EQ-5D-5L (Chinese version) | Baseline, 8 weeks, and 12 weeks | Change in health-related quality of life (HRQOL) across five domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) as measured by the Chinese EQ-5D-5L; higher scores indicate better quality of life. |
| Secondary | Hong Kong - Pain Catastrophizing Scale (HK-PCS) | Baseline, 8 weeks, and 12 weeks | Change in pain catastrophizing as measured by the 13-item HK-PCS, covering rumination, magnification, and helplessness. Higher scores indicate more catastrophic thinking. |
| Secondary | General Self-Efficacy Scale (Chinese version) | Baseline, 8 weeks, and 12 weeks | Change in self-efficacy, measured using the 10-item General Self-Efficacy Scale. Higher scores reflect greater confidence in overcoming obstacles. |
| Other | Digital Engagement Metrics (WhatsApp) | Over 8 weeks | WhatsApp read receipts, message response rates, and self-reported adherence to digital self-management content. |
| Other | Chinese System Usability Scale | 8 weeks | Usability of WhatsApp-delivered self-management content assessed by the 10-item Chinese System Usability Scale. Scores range from 0 (lowest) to 100 (highest usability). |
| Other | Participant Satisfaction with Hybrid Delivery | 8 weeks and 12 weeks | Participant-reported satisfaction and perceived benefit of receiving hybrid/integrated telehealth consultations, measured via feedback forms. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07902778
GET https://conductscience.org/api/trials/v1/NCT07902778/registered